Accessible Synthetic Biology Raises New Concerns for DIY Biological Warfare
By Joseph Neighbor,
VICE Motherboard
| 08. 23. 2016
This December, the signatory nations of the Biological Weapons Convention (BWC) will meet, as they do every five years, to discuss the state of bioweapons globally. In at least one way, the world has radically changed since they last met, in 2011. The discovery of several novel gene-editing techniques, most famous being CRISPR-Cas9, might be the scientific breakthrough of this century. It has unleashed a torrent of studies that aim to cure everything from cancer to world hunger.
But this new era of synthetic biology has a dark side. Scientific discoveries generally outpace our ability to legislate sensible limits, or even understand exactly what we’re playing with; that’s the point of experimental research, after all: to chart the unknown. The discovery last year that scientists in China have begun using gene-editing techniques on human embryos—a troubling, unprecedented step towards a sci-fi dystopia —has ignited a vigorous global debate about the limits we ought to have when manipulating biology.
The advent of CRISPR has corresponded with a widespread democratization of biology. Gene-editing kits are cheap, legal, and relatively easy to...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...